Merck to buy Terns for $6.7B, taking a leukemia drug that could challenge Scemblix - Endpoints News

Merck to acquire Terns Pharmaceuticals, gaining TERN-701 for chronic myeloid leukemia treatment. Deal strengthens oncology pipeline ahead of Keytruda patent cliff.

You will be redirected in 10 seconds.